Literature DB >> 2060525

Role of clindamycin in the treatment of acute toxoplasmosis of the central nervous system.

B Ruf1, H D Pohle.   

Abstract

Cerebral toxoplasmosis related to AIDS was treated with a combination regimen of pyrimethamine, clindamycin, and spiramycin, and in a second trial with a combination of pyrimethamine and clindamycin. Both regimens proved to be equally effective. The experience with the second trial shows that spiramycin does not provide additional benefit. Myelosuppressive side-effects due to pyrimethamine were prevented in most cases by addition of folinic acid to the regimen at the start of the antitoxoplasmic therapy. These data suggest that the combination of pyrimethamine and clindamycin is an effective alternative to the commonly used regimen consisting of pyrimethamine and sulfonamides.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2060525     DOI: 10.1007/bf01964457

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  10 in total

1.  Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy.

Authors:  C Leport; F Raffi; S Matheron; C Katlama; B Regnier; A G Saimot; C Marche; C Vedrenne; J L Vilde
Journal:  Am J Med       Date:  1988-01       Impact factor: 4.965

2.  An open study of the pyrimethamine-clindamycin combination in AIDS patients with brain toxoplasmosis.

Authors:  C Leport; S Bastuji-Garin; C Perronne; D Salmon; C Marche; F Briçaire; J L Vilde
Journal:  J Infect Dis       Date:  1989-09       Impact factor: 5.226

Review 3.  AIDS commentary. Toxoplasmic encephalitis.

Authors:  B J Luft; J S Remington
Journal:  J Infect Dis       Date:  1988-01       Impact factor: 5.226

4.  Cutaneous reaction to trimethoprim-sulfamethoxazole in patients with AIDS and Kaposi's sarcoma.

Authors:  R Mitsuyasu; J Groopman; P Volberding
Journal:  N Engl J Med       Date:  1983-06-23       Impact factor: 91.245

5.  Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome.

Authors:  F M Gordin; G L Simon; C B Wofsy; J Mills
Journal:  Ann Intern Med       Date:  1984-04       Impact factor: 25.391

6.  Central-nervous-system toxoplasmosis in homosexual men and parenteral drug abusers.

Authors:  B Wong; J W Gold; A E Brown; M Lange; R Fried; M Grieco; D Mildvan; J Giron; M L Tapper; C W Lerner
Journal:  Ann Intern Med       Date:  1984-01       Impact factor: 25.391

Review 7.  Toxoplasmosis and the acquired immune deficiency syndrome.

Authors:  R E Holliman
Journal:  J Infect       Date:  1988-03       Impact factor: 6.072

8.  Toxoplasmic encephalitis in patients with acquired immune deficiency syndrome.

Authors:  B J Luft; R G Brooks; F K Conley; R E McCabe; J S Remington
Journal:  JAMA       Date:  1984-08-17       Impact factor: 56.272

Review 9.  Current recommendations and future prospects in the treatment of toxoplasmosis.

Authors:  R E McCabe; S Oster
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

10.  Assessment of therapy for toxoplasma encephalitis. The TE Study Group.

Authors:  H W Haverkos
Journal:  Am J Med       Date:  1987-05       Impact factor: 4.965

  10 in total
  6 in total

1.  Effect of clindamycin on intracellular replication, protein synthesis, and infectivity of Toxoplasma gondii.

Authors:  J Blais; C Tardif; S Chamberland
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

2.  Antibiotic-associated diarrhea in HIV-infected patients receiving clindamycin.

Authors:  H Slevogt; B Ruf
Journal:  Infection       Date:  1997 May-Jun       Impact factor: 3.553

Review 3.  Drug treatment of HIV-related opportunistic infections.

Authors:  M E Klepser; T B Klepser
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

4.  Paradoxical effect of clindamycin in experimental, acute toxoplasmosis in cats.

Authors:  M G Davidson; M R Lappin; J R Rottman; M B Tompkins; R V English; A T Bruce; J Jayawickrama
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

5.  Efficacy of pyrimethamine/sulfadoxine in the prevention of toxoplasmic encephalitis relapses and Pneumocystis carinii pneumonia in HIV-infected patients.

Authors:  B Ruf; D Schürmann; F Bergmann; W Schüler-Maué; T Grünewald; H J Gottschalk; H Witt; H D Pohle
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

Review 6.  Toxoplasmic encephalitis relapse rates with pyrimethamine-based therapy: systematic review and meta-analysis.

Authors:  Mark P Connolly; Elizabeth Goodwin; Carina Schey; Jacqueline Zummo
Journal:  Pathog Glob Health       Date:  2017-01-16       Impact factor: 2.894

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.